Pay in 4 interest-free payments of $5.31 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Discuss whether GLP-1 therapy is appropriate for concurrent diabetes or obesity, potential drug interactions with DMARDs, realistic expectations about anti-inflammatory effects, and coordination between your rheumatology and endocrinology care teams
Both are FDA-approved for chronic weight management
Based on PSGs Artemetrx analysis for the calendar year 2023, we observed 50% of patients adherent to Ozempic (defined as a proportion of days (PDC) greater than or equal to eighty percent)and an overall PDC of 68%, compared to an adherence rate of 42% and PDC of 60% for Wegovy
Your preference has been updated for this session
NCR(-) group 3 innate lymphoid cells orchestrate IL-23/IL-17 axis to promote hepatocellular carcinoma development
See "What are the possible side effects of Janumet?" for information about increased risk of low blood sugar
